



(51) International Patent Classification:

A61K 47/02 (2006.01) A61K 9/08 (2006.01)
 A61K 47/18 (2017.01) A61K 47/26 (2006.01)
 A61K 9/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/071562

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

05 April 2022 (05.04.2022)

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the
 claims and to be republished in the event of receipt of
 amendments (Rule 48.2(h))
 — with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/171,429 06 April 2021 (06.04.2021) US

(71) Applicant: JAZZ PHARMACEUTICALS IRELAND

LTD. [IE/IE]; Fifth Floor, Waterloo Exchange, Waterloo
 Road, Dublin, 4 (IE).

(72) Inventors: KANAPURAM, Sekhar; c/o Jazz Pharmaceu-

ticals Ireland Ltd., Fifth Floor, Waterloo Exchange, Water-
 loo Road, Dublin 4 (IE). MAITY, Haripada; c/o Jazz Phar-
 maceuticals Ireland Ltd., Fifth Floor, Waterloo Exchange,
 Waterloo Road, Dublin 4 (IE). JIANG, Guifeng; c/o Jazz
 Pharmaceuticals Ireland Ltd., Fifth Floor, Waterloo Ex-
 change, Waterloo Road, Dublin 4 (IE). NARWAL, Roja;
 c/o Jazz Pharmaceuticals Ireland Ltd., Fifth Floor, Waterloo
 Exchange, Waterloo Road, Dublin, 4 (IE).

(74) Agent: ZHONG, Qiwen et al.; Morrison & Foerster LLP,

755 Page Mill Road, Palo Alto, California 94304-1018
 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
 KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
 RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
 ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: FORMULATIONS OF L-ASPARAGINASE

(57) Abstract: Provided herein are stable, aqueous, non-lyophilized formulations of L-asparaginase. Also provided herein are methods of using such formulations in the treatment of one or more diseases, disorders, or conditions (for example, cancers such as Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)) that are treatable by asparagine depletion.